A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)
Frequency of AEs. Safety will also be evaluated through vital signs, ECGs, and clinical laboratory assessments.
Endpoint detail
Change from baseline in HbA1c at Month 6., Matsuda index, and glucose AUC response to glucose tolerance test. Change from baseline in HOMA-IR, Plasma concentrations of ALN-4324 and potential metabolite(s).
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.